Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Chen, Po Hsun ^a   Tsai, Yi Ting ^a   Wang, Jun Sing ^a   Lin, Shi Dou ^b   Lee, Wen Jane ^a   Su, Shih Li ^b   Lee, I Te ^a,c   Tu, Shih Te ^b   Tseng, Yao Hsien ^a   Sheu, Wayne H H ^a,c,d,e   Lin, Shih Yi ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Beta cell function; Disposition index; Glycated hemoglobin; Glycemic control; Metformin

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; POSTPRANDIAL STATE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84902532676     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-68     Document Type: Article

References (33)

1. Pathogenesis of type 2 diabetes mellitus. DeFronzo RA, Med Clin North A 2004 88 787 835 ix 10.1016/j.mcna.2004.04.013
2. U.K. Prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective diabetes study group, Diabetes 1995 44 1249 1258 7589820
3. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR, Diabet Med 1998 15 290 296 10.1002/(SICI)1096-9136(199804)15:4<290::AID- DIA570>3.0.CO;2-M 9585393
4. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Wang JS, Tu ST, Lee IT, Lin SD, Lin SY, Su SL, Lee WJ, Sheu WH, Diabetes Metab Res Rev 2011 27 79 84 10.1002/dmrr.1149 21218511
5. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB, JAMA 2009 301 2129 2140 10.1001/jama.2009.726 19470990
6. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Fukushima M, Suzuki H, Seino Y, Diabetes Res Clin Pract 2004 66 Suppl 1 37 S43 15563978
7. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes A, European Association for the Study of D, Diabetes Care 2012 35 1364 1379 10.2337/dc12-0413 22517736
8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH, Clin Ther 2011 33 1932 1942 10.1016/j.clinthera.2011.10.014 22078152
9. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
10. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Matsuda M, DeFronzo RA, Diabetes Care 1999 22 1462 1470 10.2337/diacare.22.9.1462 10480510
11. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Phillips DI, Clark PM, Hales CN, Osmond C, Diabet Med 1994 11 286 292 10.1111/j.1464-5491.1994.tb00273.x 8033528
12. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza R, Am J Physiol Endocrinol Metab 2007 293 1 E15 10.1152/ajpendo.00421.2006 17341552
13. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. Maki KC, Rains TM, Dicklin MR, Bell M, Diabetes Technol Ther 2010 12 895 900 10.1089/dia.2010.0083 20879960
14. Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test. Maki KC, Kelley KM, Lawless AL, Hubacher RL, Schild AL, Dicklin MR, Rains TM, Diabetes Technol Ther 2011 13 661 666 10.1089/dia.2010.0240 21457067
15. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. Bergman RN, Phillips LS, Cobelli C, J Clin Invest 1981 68 1456 1467 10.1172/JCI110398 7033284
16. Accurate assessment of beta-cell function: the hyperbolic correction. Bergman RN, Ader M, Huecking K, Van Citters G, Diabetes 2002 51 Suppl 1 212 S220 11815482
17. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE, Diabetes Care 2009 32 335 341 18957530
18. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K, Int J Clin Pract 2011 65 602 612 10.1111/j.1742-1241.2010.02619.x 21489084
19. Factors associated with poor glycemic control among patients with type 2 diabetes. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K, J Diabetes Complications 2010 24 84 89 10.1016/j.jdiacomp.2008.12.008 19282203
20. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M, BMC Public Health 2005 5 36 10.1186/1471-2458-5-36 15833140
21. Five stages of evolving beta-cell dysfunction during progression to diabetes. Weir GC, Bonner-Weir S, Diabetes 2004 53 Suppl 3 16 S21 15561905
22. Assessment of beta cell function in subjects with newly diagnosed type 2 diabetes. Cernea S, Huţanu A, Coroş L, Dobreanu M, Revista Românǎ de Medicinǎ de Laborator 2013 21 145 160
23. Associations of glucose control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting type 2 diabetes. Albarrak AI, Luzio SD, Chassin LJ, Playle RA, Owens DR, Hovorka R, J Clin Endocrinol Metab 2002 87 198 203 11788647
24. The relation between parameters from homeostasis model assessment and glycemic control in type 2 diabetes. Dansuntornwong B, Chanprasertyothin S, Jongjaroenprasert W, Ngarmukos C, Bunnag P, Puavilai G, Ongphiphadhanakul B, J Med Assoc Thai 2007 90 2284 2290 18181308
25. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E, Diabetes Care 2009 32 1058 1062 10.2337/dc08-1956 19244086
26. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Shim WS, Kim SK, Kim HJ, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS, Eur J Endocrinol 2006 155 615 622 10.1530/eje.1.02249 16990662
27. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Phillips P, Karrasch J, Scott R, Wilson D, Moses R, Diabetes Care 2003 26 269 273 10.2337/diacare.26.2.269 12547847
28. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, DeFronzo RA, Diabetes 1984 33 838 845 10.2337/diab.33.9.838 6432610
29. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM, Diabetes 1984 33 346 354 10.2337/diab.33.4.346 6423429
30. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Beck-Nielsen H, Hother-Nielsen O, Pedersen O, Diabet Med 1988 5 613 620 10.1111/j.1464-5491.1988.tb01068.x 2975544
31. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A, Diabetes Metab 2002 28 195 200 12149599
32. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D, Diabetes Care 2000 23 1162 1167 10.2337/diacare.23.8.1162 10937515
33. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Rosak C, Hofmann U, Paulwitz O, Diabetes Nutr Metab 2004 17 137 142 15334790